MX9605613A - Procedimiento para preparar formas anhidras e hidratadas de derivados de piperidina antihistaminica, polimorfos y pseudomorfos de los mismos. - Google Patents

Procedimiento para preparar formas anhidras e hidratadas de derivados de piperidina antihistaminica, polimorfos y pseudomorfos de los mismos.

Info

Publication number
MX9605613A
MX9605613A MX9605613A MX9605613A MX9605613A MX 9605613 A MX9605613 A MX 9605613A MX 9605613 A MX9605613 A MX 9605613A MX 9605613 A MX9605613 A MX 9605613A MX 9605613 A MX9605613 A MX 9605613A
Authority
MX
Mexico
Prior art keywords
polymorphs
processes
pseudormophs
piperidine derivatives
preparing anhydrous
Prior art date
Application number
MX9605613A
Other languages
English (en)
Inventor
Daniel Randolph Henton
Frederick Joseph Mccarty
Susan Irene Tripp
Jill Elizabeth Dewitt
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26937420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9605613(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Publication of MX9605613A publication Critical patent/MX9605613A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion se refiere a procedimientos novedosos para preparar formas anhidras e hidratadas de derivados de piperidina, sus polimorfos y pseudomorfos de las formulas (I) y (II), que son utiles como antihistaminas, agentes antialérgicos y broquiodilatadores.
MX9605613A 1994-05-18 1995-04-28 Procedimiento para preparar formas anhidras e hidratadas de derivados de piperidina antihistaminica, polimorfos y pseudomorfos de los mismos. MX9605613A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24573194A 1994-05-18 1994-05-18
US41716195A 1995-04-11 1995-04-11
PCT/US1995/004942 WO1995031437A1 (en) 1994-05-18 1995-04-28 Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof

Publications (1)

Publication Number Publication Date
MX9605613A true MX9605613A (es) 1998-05-31

Family

ID=26937420

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9605613A MX9605613A (es) 1994-05-18 1995-04-28 Procedimiento para preparar formas anhidras e hidratadas de derivados de piperidina antihistaminica, polimorfos y pseudomorfos de los mismos.

Country Status (18)

Country Link
US (12) US20010025106A1 (es)
EP (3) EP1178041A1 (es)
JP (7) JPH10500134A (es)
CN (3) CN1148849A (es)
AT (1) ATE220667T1 (es)
AU (1) AU693892B2 (es)
CA (3) CA2449419C (es)
DE (1) DE69527429T2 (es)
DK (1) DK0766668T3 (es)
ES (1) ES2176329T3 (es)
FI (1) FI964565A (es)
HK (2) HK1098467A1 (es)
HU (1) HU227676B1 (es)
IL (3) IL113747A (es)
MX (1) MX9605613A (es)
NO (1) NO315319B1 (es)
PT (1) PT766668E (es)
WO (1) WO1995031437A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9400555D0 (en) * 1994-01-13 1994-03-09 Short Brothers Plc Boundery layer control in aerodynamic low drag structures
MX9605613A (es) 1994-05-18 1998-05-31 Hoechst Marion Roussel Inc Procedimiento para preparar formas anhidras e hidratadas de derivados de piperidina antihistaminica, polimorfos y pseudomorfos de los mismos.
EP0812195B1 (en) 1995-02-28 2002-10-30 Aventis Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol compounds
NZ501248A (en) * 1997-08-26 2001-06-29 Aventis Pharma Inc Pharmaceutical composition for combination of piperidinoalkanol-decongestant
IN191492B (es) * 1999-05-25 2003-12-06 Ranbaxy Lab Ltd
US6613906B1 (en) * 2000-06-06 2003-09-02 Geneva Pharmaceuticals, Inc. Crystal modification
CH695216A5 (de) 2001-02-23 2006-01-31 Cilag Ag Verfahren zur Herstellung eines nicht hydratisierten Salzes eines Piperidinderivats und eine so erhältliche neue kristalline Form eines solchen Salzes.
CA2444456A1 (en) * 2001-04-09 2002-10-17 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine hydrochloride
US20030021849A1 (en) * 2001-04-09 2003-01-30 Ben-Zion Dolitzky Polymorphs of fexofenadine hydrochloride
US7700779B2 (en) * 2001-06-18 2010-04-20 Dr. Reddy's Laboratories Limited Crystalline forms of fexofenadine and its hydrochloride
MXPA03011728A (es) * 2001-06-18 2004-07-08 Reddyaes Lab Ltd Formas cristalinas novedosas del acido 4-[4-[4- (hidroxidifenilmetil) -1-piperidinil] -1-hidroxibutil] -alfa, alfa -dimetilbencen acetico y su clorohidrato.
EP1414453B1 (en) * 2001-07-31 2008-03-19 Texcontor Etablissement Fexofenadine hydrochloride polymorph
US20030158227A1 (en) * 2001-11-08 2003-08-21 Barnaba Krochmal Polymorphs of fexofenadine base
WO2003104197A1 (en) * 2002-06-10 2003-12-18 Teva Pharmaceutical Industries Ltd. Polymorphic form xvi of fexofenadine hydrochloride
JP3910907B2 (ja) * 2002-10-29 2007-04-25 新光電気工業株式会社 キャパシタ素子及びこの製造方法、半導体装置用基板、並びに半導体装置
ES2322592T3 (es) * 2003-07-03 2009-06-23 Teva Pharmaceutical Industries Ltd. Formas cristalinas de acido zoledronico, formas cristlinas de la sal sodica de zoledronato, sal sodica de zoledronato amorfa y procedimientos para su preparacion.
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
EP1628959A2 (en) * 2004-04-26 2006-03-01 Teva Pharmaceutical Industries Ltd Crystalline forms of fexofenadine hydrochloride and processes for their preparation
ITMI20041143A1 (it) * 2004-06-08 2004-09-08 Dipharma Spa Polimorfi di fexofenadina e procedimento per la loro preparazione
EP1616861A3 (en) * 2004-06-15 2006-02-08 Dipharma S.p.A. A process for the preparation of keto compounds
ITMI20041568A1 (it) * 2004-07-30 2004-10-30 Dipharma Spa "polimorfi di fexofenadina base"
EP1685106A2 (en) * 2004-09-28 2006-08-02 Teva Pharmaceutical Industries, Inc. Fexofendadine crystal form and processes for its preparation thereof
DOP2006000274A (es) * 2005-12-14 2007-10-15 Sanofi Aventis Us Llc Formulación de suspensión de fexofenadina
EP2046299A1 (en) * 2006-07-11 2009-04-15 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
US20090076080A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched fexofenadine
US20090306135A1 (en) 2008-03-24 2009-12-10 Mukesh Kumar Sharma Stable amorphous fexofenadine hydrochloride
US20100183717A1 (en) * 2009-01-16 2010-07-22 Kristin Arnold Controlled-release formulations
KR20120115492A (ko) 2009-11-06 2012-10-18 바스프 에스이 ４―히드록시 벤조산 및 선택된 살충제의 결정질 복합체
WO2011158262A1 (en) 2010-06-15 2011-12-22 Chemelectiva S.R.L. Polymorphic form of fexofenadine hydrochloride, intermediates and process for its preparation
IT1400965B1 (it) * 2010-06-15 2013-07-05 Dipharma Francis Srl Polimorfi di fexofenadina
US9420872B2 (en) * 2010-08-23 2016-08-23 Jason Bird Apparatus and system for holding game-calling devices
JP2012087100A (ja) * 2010-10-21 2012-05-10 Sumitomo Chemical Co Ltd 形態ｉのフェキソフェナジン一塩酸塩の製造方法
CN104072402B (zh) * 2014-07-16 2016-08-17 昆山龙灯瑞迪制药有限公司 一种新结晶形式的盐酸非索非那定化合物及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US631375A (en) * 1899-04-12 1899-08-22 Ephraim Musselman Face-protector.
US3448152A (en) * 1966-11-03 1969-06-03 Jefferson Chem Co Inc Amine recovery
US3965257A (en) * 1972-01-28 1976-06-22 Richardson-Merrell Inc. Compositions and methods for the treatment of the symptoms of histamine induced allergic reactions
US3878217A (en) * 1972-01-28 1975-04-15 Richardson Merrell Inc Alpha-aryl-4-substituted piperidinoalkanol derivatives
BE794598A (fr) * 1972-01-28 1973-05-16 Richardson Merrell Inc Nouveaux derives olefiniques de piperidines substituees en 4 et leur procede de preparation
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4254130A (en) 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4285958A (en) * 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkylene ketones, pharmaceutical compositions thereof and method of use thereof
US4285957A (en) * 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4742175A (en) * 1986-05-07 1988-05-03 Merrell Dow Pharmaceuticals Inc. Preparation of polymorphically pure terfenadine
JPH02213431A (ja) * 1989-02-13 1990-08-24 Kobe Steel Ltd ＳｉＣウィスカ強化Ａｌ合金複合材料
DE4034218A1 (de) 1990-10-27 1992-04-30 Merck Patent Gmbh Verfahren zur herstellung von carebastin
TW198008B (es) * 1991-04-08 1993-01-11 Green Cross Corp
US5631375A (en) * 1992-04-10 1997-05-20 Merrell Pharmaceuticals, Inc. Process for piperidine derivatives
DK0635004T3 (da) 1992-04-10 2002-11-11 Merrell Pharma Inc 4-Diphenylmethylpiperidinderivater og fremgangsmåde til fremstilling deraf
DE69320952T2 (de) 1992-05-11 1999-05-27 Merrell Pharma Inc Verwendung von terfenadin-derivaten als antihistaminika in leberkranken patienten
ES2284740T3 (es) 1992-08-03 2007-11-16 Sepracor Inc. Carboxilato de terfenadina y el tratamiento de la irritacion cutanea.
US5315016A (en) 1992-10-13 1994-05-24 Nycomed Dak A/S Process for preparing pure podophyllotoxin
ATE174589T1 (de) * 1993-06-24 1999-01-15 Albany Molecular Res Inc Verfahren zur herstellung von piperidinderivaten
CA2181089C (en) 1993-06-24 2000-05-23 Thomas E. D'ambra Piperidine derivatives and process for their production
CA2362337C (en) 1993-06-25 2005-08-02 Merrell Pharmaceuticals Inc. Novel intermediates for the preparation of antihistaminic 4-diphenylmethyl/diphenylmethoxy piperidine derivatives
US6147216A (en) 1993-06-25 2000-11-14 Merrell Pharmaceuticals Inc. Intermediates useful for the preparation of antihistaminic piperidine derivatives
MX9605613A (es) 1994-05-18 1998-05-31 Hoechst Marion Roussel Inc Procedimiento para preparar formas anhidras e hidratadas de derivados de piperidina antihistaminica, polimorfos y pseudomorfos de los mismos.
US5576610A (en) * 1994-07-05 1996-11-19 Motorola, Inc. Method and apparatus for determining battery characteristics
EP0812195B1 (en) * 1995-02-28 2002-10-30 Aventis Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol compounds
IL134771A (en) 1995-02-28 2002-02-10 Aventis Pharma Inc Pharmaceutical compositions of piperidinoalkanol compounds in solid unit dosage form
US5574045A (en) * 1995-06-06 1996-11-12 Hoechst Marion Roussel, Inc. Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
NZ501248A (en) * 1997-08-26 2001-06-29 Aventis Pharma Inc Pharmaceutical composition for combination of piperidinoalkanol-decongestant
US6214427B1 (en) * 1998-08-28 2001-04-10 General Electric Company Method of making an electronic device having a single crystal substrate formed by solid state crystal conversion
US6613906B1 (en) 2000-06-06 2003-09-02 Geneva Pharmaceuticals, Inc. Crystal modification
US20020177680A1 (en) * 2000-08-23 2002-11-28 Hubbell Jeffrey A. Novel polymer compounds
US6475942B1 (en) * 2000-09-05 2002-11-05 General Electric Company Conversion of polycrystalline alumina to single crystal sapphire using molybdenum doping
CA2444456A1 (en) * 2001-04-09 2002-10-17 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine hydrochloride
US7700779B2 (en) * 2001-06-18 2010-04-20 Dr. Reddy's Laboratories Limited Crystalline forms of fexofenadine and its hydrochloride
US20090211514A1 (en) * 2008-02-26 2009-08-27 Lehigh University Single crystal conversion process

Also Published As

Publication number Publication date
CN1907967B (zh) 2012-07-04
HU227676B1 (en) 2011-11-28
EP0766668A1 (en) 1997-04-09
ATE220667T1 (de) 2002-08-15
CA2585705C (en) 2012-04-17
AU2426595A (en) 1995-12-05
DE69527429D1 (de) 2002-08-22
EP1178041A1 (en) 2002-02-06
HU9603167D0 (en) 1997-01-28
US20020193600A1 (en) 2002-12-19
US20070021461A1 (en) 2007-01-25
IL134917A0 (en) 2001-05-20
IL113747A (en) 2001-05-20
NO964859L (no) 1996-11-15
DE69527429T2 (de) 2003-03-20
JP4503908B2 (ja) 2010-07-14
NO964859D0 (no) 1996-11-15
HUT76134A (en) 1997-06-30
JP2010120969A (ja) 2010-06-03
US20010012896A1 (en) 2001-08-09
US20080167469A1 (en) 2008-07-10
US20080167471A1 (en) 2008-07-10
CN1148849A (zh) 1997-04-30
JP2002308850A (ja) 2002-10-23
FI964565A0 (fi) 1996-11-14
US7662835B2 (en) 2010-02-16
HK1137742A1 (en) 2010-08-06
US7135571B2 (en) 2006-11-14
JP2002255935A (ja) 2002-09-11
US7138524B2 (en) 2006-11-21
IL134917A (en) 2001-07-24
JP2002316978A (ja) 2002-10-31
DK0766668T3 (da) 2002-10-28
CA2585705A1 (en) 1995-11-23
CA2189007C (en) 2004-03-02
EP0766668B1 (en) 2002-07-17
FI964565A (fi) 1996-11-14
US20020193603A1 (en) 2002-12-19
CA2189007A1 (en) 1995-11-23
PT766668E (pt) 2002-11-29
JPH10500134A (ja) 1998-01-06
HK1098467A1 (en) 2007-07-20
CA2449419C (en) 2011-09-06
CA2449419A1 (en) 1995-11-23
JP4503907B2 (ja) 2010-07-14
US20040014976A1 (en) 2004-01-22
JP4503909B2 (ja) 2010-07-14
US20070021462A1 (en) 2007-01-25
US20010014741A1 (en) 2001-08-16
NO315319B1 (no) 2003-08-18
IL113747A0 (en) 1995-08-31
US20030045721A1 (en) 2003-03-06
AU693892B2 (en) 1998-07-09
CN1907967A (zh) 2007-02-07
WO1995031437A1 (en) 1995-11-23
US20010025106A1 (en) 2001-09-27
US20020193601A1 (en) 2002-12-19
ES2176329T3 (es) 2002-12-01
EP2354125A1 (en) 2011-08-10
JP2002308849A (ja) 2002-10-23
CN1623985A (zh) 2005-06-08
JP2002255936A (ja) 2002-09-11
US7666881B2 (en) 2010-02-23

Similar Documents

Publication Publication Date Title
MX9605613A (es) Procedimiento para preparar formas anhidras e hidratadas de derivados de piperidina antihistaminica, polimorfos y pseudomorfos de los mismos.
HU9301361D0 (en) Method for producing 4-aryl-piperazines and 4-aryl-piperidines
HU9302733D0 (en) Process for producing heterocyclic amine derivatives
DK1200418T3 (da) Nematodicide trifluorbutener
DE69709938T2 (de) N-benzylpiperidin- und tetrahydropyridin-derivate
BG105028A (en) Bridged indenopyrrolocarbazoles
TW362096B (en) Novel piperidine derivatives and the process for preparing the same
YU12000A (sh) Supstituisani 1,2,3,4,5,6-heksahidro-2,6-metano-3-benzazocin -10-oli, postupak za njihovo pripremanje i njihova primena kao lekova
IN187760B (es)
HU906010D0 (en) New substituted alkyl-piperidine derivatives
MX9500228A (es) N-oxidos de 4-arilpiperazinas y 4-arilpiperidinas.
ZA983231B (en) Substituted benzyloxyimino compounds.
ES8505363A1 (es) Un procedimiento para preparar una 3-(2-furoil)-5-2,6-dimetil-4-(2-nitrofenil)-1,4-dihidropiridina
MX9603450A (es) Procedimiento para la obtencion de aminotriazolinas substituidas.
IT1256925B (it) Impiego di frammenti o/e di derivati della timosina alfa 1.
MY127539A (en) Bridged indenopyrrolocarbazoles
DE59911958D1 (de) Fluorierte 3,4-dihydrochinolin-derivative als nos-inhibitoren